NASDAQ:CBIO Crescent Biopharma (CBIO) Stock Price, News & Analysis $20.74 +0.51 (+2.52%) Closing price 04:00 PM EasternExtended Trading$20.68 -0.06 (-0.31%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Crescent Biopharma Stock (NASDAQ:CBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Crescent Biopharma alerts:Sign Up Key Stats Today's Range$19.47▼$21.2450-Day Range$10.35▼$26.9852-Week Range$8.72▼$27.41Volume140,396 shsAverage Volume231,313 shsMarket Capitalization$571.59 millionP/E RatioN/ADividend YieldN/APrice Target$28.00Consensus RatingBuy Company Overview Crescent Biopharma, Inc. (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth. The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis. In parallel, Crescent is advancing an oncolytic adenovirus program engineered to selectively infect and lyse cancer cells, thereby releasing tumor antigens and amplifying systemic immune responses. Additional preclinical assets explore complementary mechanisms to address resistance in solid tumors. Research and development activities are conducted primarily in the United States, leveraging a proprietary platform that integrates molecular engineering with immuno‐oncology expertise. Crescent collaborates with contract research organizations and academic institutions to optimize candidate selection, advance preclinical studies and prepare for clinical evaluation. Founded in 2020 and headquartered in Woodland Hills, California, Crescent Biopharma is led by a management team and scientific advisory board with extensive experience in oncology drug discovery, biologics development and clinical operations. The company is focused on progressing its pipeline through IND-enabling studies and early‐phase clinical trials.AI Generated. May Contain Errors. Read More Crescent Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCBIO MarketRank™: Crescent Biopharma scored higher than 48% of companies evaluated by MarketBeat, and ranked 716th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingBuy Consensus RatingCrescent Biopharma has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 3 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCrescent Biopharma has a consensus price target of $28.00, representing about 35.0% upside from its current price of $20.74.Amount of Analyst CoverageCrescent Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Crescent Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Crescent Biopharma are expected to decrease in the coming year, from ($3.22) to ($3.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crescent Biopharma is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crescent Biopharma is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrescent Biopharma has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Crescent Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.52% of the float of Crescent Biopharma has been sold short.Short Interest Ratio / Days to CoverCrescent Biopharma has a short interest ratio ("days to cover") of 8.87.Change versus previous monthShort interest in Crescent Biopharma has recently increased by 7.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrescent Biopharma does not currently pay a dividend.Dividend GrowthCrescent Biopharma does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.57 News SentimentCrescent Biopharma has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Crescent Biopharma this week, compared to 3 articles on an average week.Search Interest5 people have searched for CBIO on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Crescent Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders4.00% of the stock of Crescent Biopharma is held by insiders.Percentage Held by Institutions75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crescent Biopharma's insider trading history. Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBIO Stock News HeadlinesCrescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology ...May 21 at 11:49 PM | markets.businessinsider.comCrescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027May 21 at 5:51 PM | quiverquant.comQYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 22 at 1:00 AM | Profits Run (Ad)Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual MeetingMay 21 at 5:30 PM | globenewswire.comCrescent Biopharma Inc CBIOMay 20 at 2:34 PM | morningstar.comMCrescent Biopharma (NASDAQ:CBIO) Trading Down 9.9% - Here's WhyMay 17, 2026 | americanbankingnews.comCrescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Buy" from AnalystsMay 13, 2026 | americanbankingnews.comCrescent Biopharma Announces Grants of Inducement AwardsMay 12, 2026 | globenewswire.comSee More Headlines CBIO Stock Analysis - Frequently Asked Questions How have CBIO shares performed this year? Crescent Biopharma's stock was trading at $11.86 at the start of the year. Since then, CBIO stock has increased by 74.9% and is now trading at $20.74. How were Crescent Biopharma's earnings last quarter? Crescent Biopharma, Inc. (NASDAQ:CBIO) posted its quarterly earnings results on Wednesday, April, 29th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.15. The biopharmaceutical company earned $1.04 million during the quarter, compared to analysts' expectations of $0.36 million. When did Crescent Biopharma's stock split? Shares of Crescent Biopharma reverse split before market open on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Crescent Biopharma IPO? Crescent Biopharma (CBIO) raised $56 million in an IPO on Friday, January 10th 2014. The company issued 7,000,000 shares at $8.00 per share. Who are Crescent Biopharma's major shareholders? Crescent Biopharma's top institutional shareholders include Exome Asset Management LLC (0.56%), Jennison Associates LLC (0.56%), ADAR1 Capital Management LLC (0.18%) and Bank of America Corp DE (0.11%). View institutional ownership trends. How do I buy shares of Crescent Biopharma? Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crescent Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV). Company Calendar Last Earnings4/29/2026Today5/22/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CBIO's financial health is in the Green zone, according to TradeSmith. CBIO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO Previous SymbolNASDAQ:CBIO CIK1253689 Webwww.crescentbiopharma.com Phone617-465-0586Fax336-480-2107Employees50Year Founded2003Price Target and Rating Average Price Target for Crescent Biopharma$28.00 High Price Target$35.00 Low Price Target$22.00 Potential Upside/Downside+35.0%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($10.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$153.94 million Net MarginsN/A Pretax Margin-1,347.11% Return on Equity-103.44% Return on Assets-88.19% Debt Debt-to-Equity RatioN/A Current Ratio13.78 Quick Ratio13.78 Sales & Book Value Annual Sales$10.84 million Price / Sales52.73 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book3.18Miscellaneous Outstanding Shares27,560,000Free Float26,455,000Market Cap$571.59 million OptionableNo Data Beta1.21 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CBIO) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOne coin wired into Elon's visionSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
